AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
Veryard
Claire
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. claire.veryard@thomson.com
D042702:Angiopoietin-2 / Q000037:antagonists & inhibitors; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009952:Ornithine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011622:Pterins / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D036104:Receptor, EphA2 / Q000276:immunology; D012958:Societies, Scientific
C423343:1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione); D042702:Angiopoietin-2; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001570:Benzodiazepinones; D011622:Pterins; D011758:Pyrroles; C085590:N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine; D009952:Ornithine; D066246:ErbB Receptors; D036104:Receptor, EphA2; C486839:intetumumab